Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGeR-PaC: Intra-arterial Gemcitabine vs IV Gemcitabine + Nab-Paclitaxel in Locally Advanced Pancreatic Cancer
NCT03257033Phase 3Active, not recruiting
- Sponsor
- RenovoRx
- Start
- Mar 2018
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by RenovoRx. Primary endpoint: Overall Survival at 5 years. Started Mar 2018; status: active, not recruiting.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03257033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257033.